Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
330
datasets available to search
ShareScore release 0.9.0
Dataset results
330 results for “anticancer”
Fig. 4 in Genomic data mining approaches for the discovery of anticancer peptides from Ganoderma sinense
Fig. 4. Length distributions of cleaved peptides. The parent proteins were cleaved by in silico enzyme digestion with trypsin. The length distributions of peptides between 7 and 19 amino acids in length are shown.
Fig. 2 in Genomic data mining approaches for the discovery of anticancer peptides from Ganoderma sinense
Fig. 2. Experimental flowchart. (A) Blast search and alignment of G. sinense proteins with known anticancer peptides. (B) An example of a Hit sequence. (C) Hit sequences were cleaved by in silico enzyme digestion of trypsin. (D) The digested fragments were screened by mACPpred, an SVM-based algorithm, to identify putative ACPs. (E) The resulting peptides were then subjected to sequence comparison to known ACPs.
Data from: Joining up the scattered anticancer knowledge on auraptene and umbelliprenin: A meta-analysis
<p>Auraptene (AUR) and umbelliprenin (UMB) are naturally occurring prenylated coumarins that have demonstrated promising anticancer effects across various human cancer cell lines. This meta-analysis aimed to systematically assess, compare, and quantify the anticancer efficacy of AUR and UMB by synthesizing evidence from in vitro studies. A comprehensive literature search identified 27 eligible studies investigating AUR or UMB against cancer cells. Mixed-effects models revealed significant negative associations between coumarin dose and viability for AUR (est. = − 2.27) and UMB (est. = − 3.990), underscoring their dose-dependent cytotoxicity. Meta-regression indicated slightly higher potency for UMB over AUR, potentially due to increased lipophilicity imparted by additional isoprenyl units. Machine learning approaches identified coumarin dose and cancer type as the most influential determinants of toxicity, while treatment duration and the specific coumarin displayed weaker effects. Moderate (AUR) to substantial (UMB) between-study heterogeneity was detected, although the findings proved robust. In summary, this meta-analysis establishes AUR and UMB as promising natural anticancer candidates with clear dose-toxicity relationships across diverse malignancies. The structural insights and quantifications of anticancer efficacy can inform forthcoming efforts assessing therapeutic potential in pre-clinical models and human trials.</p>
Repurposing Metformin as Anticancer Drug: in Advanced Prostate Cancer
ClinicalTrials.gov study NCT03137186. IPD Sharing: NO. Countries: 1. Publications: 12.
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
ClinicalTrials.gov study NCT05179603. IPD Sharing: YES. Countries: 3. Publications: 0.
TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography
ClinicalTrials.gov study NCT06310330. IPD Sharing: NO. Countries: 1. Publications: 1.
Evaluation of Reporting of AdVerse Events Associated With AnTicAncer theRapy (AVATAR)
ClinicalTrials.gov study NCT04696250. IPD Sharing: NO. Countries: 1. Publications: 1.
Collaborative Network to Take Responsibility for Oral Anticancer Therapy 2
ClinicalTrials.gov study NCT04142463. IPD Sharing: NO. Countries: 1. Publications: 1.
Impact of the DROP Program on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients with Risk Factors
ClinicalTrials.gov study NCT03257969. IPD Sharing: NO. Countries: 1. Publications: 1.
Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer
ClinicalTrials.gov study NCT01111591. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Benefit of Adding Cureety TechCare Telemonitoring to Usual Care During Injectable Anticancer Treatment
ClinicalTrials.gov study NCT06371911. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Optimization of the Targeted Anticancer Therapies
ClinicalTrials.gov study NCT04484064. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
ClinicalTrials.gov study NCT04008797. IPD Sharing: YES. Countries: 10. Publications: 2.
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
ClinicalTrials.gov study NCT02652975. IPD Sharing: NO. Countries: 1. Publications: 1.
A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer
ClinicalTrials.gov study NCT02138422. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Treatment
ClinicalTrials.gov study NCT04440800. IPD Sharing: NO. Countries: 1. Publications: 5.
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
ClinicalTrials.gov study NCT05061420. IPD Sharing: YES. Countries: 11. Publications: 0.
Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring
ClinicalTrials.gov study NCT01326767. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Study of ORIC-101 in Combination With Anticancer Therapy
ClinicalTrials.gov study NCT03928314. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Medico-economic Evaluation of the ONCORAL Program for Ambulatory Patients Under Oral Anticancer Drugs Versus Usual Care
ClinicalTrials.gov study NCT03660670. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.